Vaccine News and Research

Latest Vaccine News and Research

Colorcon acquires NP Pharm

Colorcon, Inc. today announced the acquisition of the full-service pharmaceutical excipient company, NP Pharm, a Division of Ethypharm. This acquisition expands Colorcon's global excipient product offerings in the pharmaceutical and nutritional markets.

23 Apr 2010

IAVI, Lentigen to design preventive AIDS vaccine

The International AIDS Vaccine Initiative and Lentigen today announced a collaboration to design a preventive AIDS vaccine based on Lentigen's technology. The candidate AIDS vaccine will be devised to safely mimic biological aspects of HIV infection and tested first in pre-clinical studies as part of an initial 18-month agreement.

23 Apr 2010

FDA Advisory Committees vote against approval of Acurox NDA

Acura Pharmaceuticals, Inc. and King Pharmaceuticals®, Inc. today announced that the U.S. Food and Drug Administration's (FDA) Anesthetic and Life Support Drugs and Drug Safety and Risk Management Committees voted that they do not have enough evidence to support the approval of the New Drug Application (NDA) for Acurox® (oxycodone HCl and niacin) Tablets for the treatment of moderate to severe pain, considering the deterrent effects of niacin as well as the potential deterrent effects of the other features specific to Acurox®.

23 Apr 2010

NeoStem signs Collaborative Research Agreement with ImmuneRegen BioSciences

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China and ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc., announced today that they have entered into a Collaborative Research Agreement, focused on the development of an advanced, adult human stem cell product.

23 Apr 2010

FDA grants conditional approval for first approved Total Spine Arthroplasty system clinical study

Flexuspine, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted conditional approval to begin the initial phase of the Investigational Device Exemption (IDE) for a feasibility study of its FSU device. This is the first approved clinical study for a Total Spine Arthroplasty system in the U.S.

23 Apr 2010

Seasonal flu vaccine causing serious side effects in under-fives: Ban on flu vaccination program

The seasonal flu vaccine has caused serious side effects in dozens of children in Western Australia (WA) and following this the Health Department has suspended further free flu vaccinations for under-fives. There has been as rise in admissions to Princess Margaret Hospital. The side effects to the flu vaccine include fever, vomiting and often seizures related to high fever, also known as febrile convulsions. One of the children is seriously ill at present.

22 Apr 2010

Codexis prices initial common stock public offering at $13.00 per share

Codexis, Inc. announced today the pricing of its initial public offering of 6,000,000 shares of its common stock, at $13.00 per share. All shares are being sold by the company. Codexis has granted the underwriters an option to purchase up to an additional 900,000 shares at the initial public offering price to cover overallotments, if any. The common stock will trade on the NASDAQ Global Market under the symbol "CDXS."

22 Apr 2010

Mystic Pharmaceuticals granted U.S. patent covering VRx2 drug delivery platform technology

Mystic Pharmaceuticals today announced it has been granted U.S. Patent 7,669,597, a key technology of its VRx2™ drug delivery platform. The VRx2™ Delivery Platform provides preservative free, precision dose delivery for ophthalmic and intranasal drugs and biologics.

22 Apr 2010

Baxter International's global sales for first-quarter advances by 11% to $3.1 billion

Baxter International Inc. today reported first quarter net income of $525 million, an increase of 2 percent from $516 million reported in the first quarter of 2009. Earnings per diluted share of $0.86 increased 4 percent from $0.83 per diluted share reported in the prior-year period. Baxter's first quarter financial results included a one-time, non-cash special charge of $39 million (or $0.07 per diluted share) related to a change in the tax treatment of post-retirement prescription drug benefits under recent U.S. healthcare reform legislation.

From Baxter International Inc. 22 Apr 2010

Vical presents Phase 2 trial results of TransVax CMV vaccine at World Vaccine Congress

Vical Incorporated announced today that the company's TransVax cytomegalovirus vaccine elicited sustained increases in both cellular and antibody immune responses compared with placebo through the final 12-month follow-up in an ongoing Phase 2 trial in hematopoietic cell transplant recipients.

22 Apr 2010

RCPSG's Faculty of Travel Medicine selects Travel Medicine and Infectious Disease as official journal

Elsevier, the world-leading publisher of scientific, technical and medical information products and services, in partnership with the Faculty of Travel Medicine of the Royal College of Physicians and Surgeons of Glasgow, announces that Travel Medicine and Infectious Disease has been chosen to become the official journal of RCPSG's Faculty of Travel Medicine.

22 Apr 2010

Removable methyl groups on specific genes of autistic individuals that led to gene silencing identified

A new study by researchers at The George Washington University School of Medicine and Health Sciences' Department of Biochemistry and Molecular Biology raises hope that autism may be more easily diagnosed and that its effects may be more reversible than previously thought.

22 Apr 2010

SGO white paper reviews current status of HPV typing, its benefits and deficiencies

The Society of Gynecologic Oncologists has published its second in a series of four papers on a variety of cervical cancer issues and topics that were the focus of its Forum "The Future Strategies for Cervical Cancer Prevention: What Do We Need to Do Now to Prepare."

22 Apr 2010

Swine flu vaccine blues

Exactly a year after the swine flu outbreak vigilance, newer vaccine techniques and other measures are being emphasized by researchers and key decision makers. Dr. Harvey Fineberg, chairman of the World Health Organization's pandemic review committee and President of the U.S. Institute of Medicine says, we need to look at the past to learn from it.

22 Apr 2010

H1N1 flu epidemic has lessons to offer health care providers: Anesthesia Progress

The H1N1 flu epidemic has lessons to offer health care providers. The limited amount of vaccine available initially left pregnant women, small children with medical conditions, and other high-risk populations waiting in long lines. The problems encountered in reaching certain segments of the population apply to the provision of dental care as well as other disciplines.

22 Apr 2010

ImmunoCellular Therapeutics, UPENN sign research agreement

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today that the Company has entered into a sponsored research agreement and an option agreement with The University of Pennsylvania to support process development and manufacturing in a planned Phase II clinical trial of ICT-107, the Company's dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme.

22 Apr 2010

AFP reflects on WHO's response to H1N1

Agence France-Presse examines the WHO's response to H1N1 (swine flu) one year since the virus was first reported in Mexico and the U.S. "A year on, questions linger as to whether a decision by the World Health Organization to declare swine flu a pandemic, thereby unleashing the slew of health measures, was over-dramatic or even tainted by commercial interests," the news service writes.

22 Apr 2010

No more needles for vaccines – a two minute Nanopatch may suffice, say researchers

Vaccines have been associated with painful injections for a very long time. In a new and important discovery researchers have developed special ‘nano patches’ that can deliver vaccines without needles in just two minutes using 100 times less dose than used conventionally.

22 Apr 2010

Celldex Therapeutics presents CDX-1127 antibody program at AACR Annual Meeting

Celldex Therapeutics, Inc. today announced that CDX-1127, a preclinical therapeutic antibody program for oncology indications, is the subject of a poster presentation at the 2010 American Association for Cancer Research 101st Annual Meeting in Washington DC.

22 Apr 2010

Merck to market and distribute MBL's Td vaccine in the U.S.

MassBiologics of the University of Massachusetts Medical School and Merck & Co., Inc. announced today that they have entered into an agreement that provides Merck with exclusive rights to market and distribute MBL's tetanus and diphtheria toxoids adsorbed (Td) vaccine in the United States, with the exception of Massachusetts, where MBL will continue distributing the vaccine.

21 Apr 2010

Vaccine News and Research

Latest Vaccine News and Research

Colorcon acquires NP Pharm

IAVI, Lentigen to design preventive AIDS vaccine

FDA Advisory Committees vote against approval of Acurox NDA

NeoStem signs Collaborative Research Agreement with ImmuneRegen BioSciences

FDA grants conditional approval for first approved Total Spine Arthroplasty system clinical study

Seasonal flu vaccine causing serious side effects in under-fives: Ban on flu vaccination program

Codexis prices initial common stock public offering at $13.00 per share

Mystic Pharmaceuticals granted U.S. patent covering VRx2 drug delivery platform technology

Baxter International's global sales for first-quarter advances by 11% to $3.1 billion

Vical presents Phase 2 trial results of TransVax CMV vaccine at World Vaccine Congress

RCPSG's Faculty of Travel Medicine selects Travel Medicine and Infectious Disease as official journal

Removable methyl groups on specific genes of autistic individuals that led to gene silencing identified

SGO white paper reviews current status of HPV typing, its benefits and deficiencies

Swine flu vaccine blues

H1N1 flu epidemic has lessons to offer health care providers: Anesthesia Progress

ImmunoCellular Therapeutics, UPENN sign research agreement

AFP reflects on WHO's response to H1N1

No more needles for vaccines – a two minute Nanopatch may suffice, say researchers

Celldex Therapeutics presents CDX-1127 antibody program at AACR Annual Meeting

Merck to market and distribute MBL's Td vaccine in the U.S.

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Newsletters you may be interested in